Findings

What do systematic reviews say?

44 questions · 49 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 8.2%GRADE not reported 0 · 0%Very low 7 · 14.3%Low 24 · 49%Moderate 13 · 26.5%High 1 · 2%

Pazopanib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 467 participants
Low

Interferon‐α alone vs standard targeted therapies

1‐year mortality · previously untreated patients with mRCC

Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.3 [1.13, 1.51]
2 studies · 1166 participants
Moderate

Interferon‐α alone vs standard targeted therapies

QoL · previously untreated patients with mRCC

5 findings from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low

Show 2 more findings

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1002 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1002 participants
Low

Interferon‐α alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1.03, 1.32]
1 study · 408 participants
Low